- Special Sections
- Public Notices
Q: I heard a new drug was approved for prostate cancer. What can you tell me about it?
A: The FDA recently (2012) approved Xtandi (enzalutamide) for the treatment of men with late-stage prostate cancer. Enzalutamide is known as an androgen receptor inhibitor, which works to decrease the growth and spread of prostate cancer cells.
If you currently subscribe or have subscribed in the past to the Citrus Chronicle, then simply find your account number on your mailing label and enter it below.
Click the question mark below to see where your account ID appears on your mailing label.